Dr Roger G Harrison PhD CEO Antares

1
(No Transcript)
2
Dr Roger G Harrison PhD - CEO Antares

• Recent History at Eli Lilly and Company
• May 99 - Feb 01 Dir. Alliances
• 97 - 99 Global Product Team Leader
• 93 - 97 Dir. Development Projects,
  Technology Planning
• 92 - 93 Dir. Technology Dev Plan
• 91 - 92 Dir. Formulations Technology
  Development
• Previous senior leadership roles in research
  (chemistry, biochemistry) and regulatory affairs

3
36 Billion Global Drug Delivery Market

• Global market expected to be 70 Billion by 2005
• Injectable market worth 16 Billion today
• Expected to double by 2005
• Biotechnology drugs are losing patent protection
• New biotechnology products will require drug
  delivery solutions to reach their potential

4
Highlights - 2001

• Permatec and Medi-ject combine - Feb 2001
• Name change to Antares Pharma
• New Management with drug delivery track record
• Dr Jacques Gonella - Chairman
• Dr Roger Harrison - CEO
• Private placement raises 10 million
• Business strategy defined
• Implementation of business plan initiated
• Headquarters in Pennsylvania

5
Antares Today.

• HQ in USA (Pennsylvania)
• RD / Manufacturing in Minneapolis, USA Basel,
  Switzerland
• Multiple drug delivery platforms
• Parenteral delivery needle-free and mini-needle
  injectors
• Transdermal delivery gels and patches
• Oral delivery fast-melt tablet
• FDA approved devices
• Products on the market

6
Antares Strategic Intent

• To create Shareholder value
• by
• providing drug delivery technology to enhance
  safety, cost effectiveness and convenience in
  todays and tomorrows medicines.

7
Our Strategy.. People, Products Partnerships

• People committed to continued innovation and
  exceeding customer expectations
• Product technologies that meet key needs today
• A focused goal to become the best in industry in
  working with pharmaceutical partners

8
Near Medium Term strategy

• Near Term
• Marry our delivery technologies with drugs of our
  partners
• Revenues from
• Development Fees
• Licensing Fees
• Milestone payments
• Royalties on sales
• Manufacturing

• Medium Term
• In addition to Near TermCapture more of the
  value split
• Partner in late stage development
• Increased revenue stream
• Higher milestones royalties

9
Delivery Technologies
10
Antares Pharma Core Technologies

• Injector devices
• Needle-free (reusable disposable systems)
• Mini-needle (unique single-shot system)
• Transdermal technology
• Innovative and patented gel delivery
• Injectable SR gel technology
• Compatible with our injector systems
• Oral melt-in-the-mouth technology

11
Antares Pharma Device Portfolio

• Needle-Free Injectors
• Antares MJ 6 (Choice) reusable, vials
• Antares MJ 7 (Vision ) next generation MJ 6
• Antares MJ 8 reusable, cartridges
• Antares MJ 10 disposable

12
Needle-Free is Well Proven

• Historical Data
• 20 years over 100 million injections (insulin)
• No significant side effects
• Clinical Data
• User studies show good subcutaneous delivery
• MRI studies show good dispersion patterns
• Shear studies indicate maintained integrity of
  relatively unstable drugs
• Pharmacokinetic studies indicate equivalence to
  needle-based systems
• User survey studies suggest high degree of user
  satisfaction

13
Proven Patient Benefits

• Well established patient benefits satisfaction
• 85 would recommend to others
• 63 experience less pain than with needles
• 62 have improved attitude toward injections
• 57 are more willing to inject

Source 1998 Medi-Jector Owners Survey
14
Ferring Preference Study

• Four week crossover study comparing Medi-Jector
  to pen injector for growth hormone
  administration
• (N18) Painful Annoying
  Ease/Use O/A Pref
• MJ 28 22 61 67
• No Difference 0 6 11 11
• Pen 72 72 28 22

Verrips et al Acta Paediatr 1998
15
Needle-Free Depth Dispersion

• Comparative MRIs show good subcutaneous delivery
• Slightly broader dispersion than conventional
  needle

Needle Syringe
Needle-Free
16
Needle-Free Injection Devices
Antares MJ 7 - Vision
Current state of the art in needle-free
injection

• Approved in USA CE marked in Europe
• Commercial status
• Currently marketed for insulin
• Licensed for growth hormone
• Two configurations developed
• Intra-muscular
• Subcutaneous
• Variable dose up to 0.5 ml
• Disposable needle-free syringe

17
Needle-Free Injection Devices
Antares MJ8
Next-generation reusable injector

• Self-contained pen style
• Discreet and convenient
• Uses standard drug cartridges
• 1.5 to 3.0 ml
• Variable dose up to 0.2 ml
• Disposable needle-free syringe

18
Needle-Free Injection Devices
Antares MJ10
Innovative pre-filled injector

• Single-shot disposable needle-free device
• Glass-in-plastic cartridge
• Proprietary manufacturing method
• Custom gas cartridge design
• Variable dose up to 0.5 ml

19
Antares Gel Technologies

• Advantages versus patches
• Lower cost
• Greater efficiency of drug delivery
• Less potential irritancy compared with occlusive
  effect of patches
• No potential for sensitivity to adhesives
• Cosmetically elegant Invisible
• Antares focus
• Alternatives to existing patch products
• Competition to patch technology for new drugs
• Continuing development of an IP position
• Sustained release gels married with Antares
  injector technology

20
Antares Transdermal Pipeline
21
Antares Pharma Device Portfolio cont

• Mini-Needle Injection Devices
• AJ1 pre-filled, subcutaneous
• AJ-ID pre-filled, intradermal

22
AJ1 Mini-Needle Device

• Mini-needle combined with low pressure jet
  injection
• Virtually no incomplete injections
• Safe in glass cartridge
• Faster injection of larger volumes than
  conventional needles
• Retracting / locking collar
• Patient never sees the needle
• Eliminates sharps hazards
• Pre-filled and assembled
• Ultimate convenience for patients
• Conventional glass cartridge stopper materials
• Improves compatibility with existing filling
  methods
• Minimizes stability and compatibility issues
• Capable of delivering up to 1.0 ml
• Proprietary technology

23
AJ1 Shot

• 0.5ml shot

24
Mini-Needle Injection Devices
AJ-ID Intradermal Device

• Modified AJ1 for intradermal vaccine delivery
• Shorter needle reduced pressure
• Clinical results show injections comparable to
  needle ID injection, and very repeatable
• Dye studies in cadavers
• MRI studies in live subjects

25
AJ-ID Clinical Results
Patient Preference

• Which device did you prefer for the
  administration of the intradermal injections?
• ID needle syringe 0
• AJ1-ID 15
• Key Reasons
• Didnt feel a thing.
• No pain. No needle.
• Cant see the needle.
• Its quick, no pain.

26
Antares Patent Portfolio

• Injector patents granted 21
• Patent applications - needle free 4
• Patent applications - mini-needle 5
• Transdermal core patents 4
• Transdermal patents granted 2